Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Simulations Plus, Inc. | simulations_8k-111815.htm |
| EX-99.2 - POWERPOINT PRESENTATION - Simulations Plus, Inc. | simulations_ex9902.htm |
Exhibit 99.1
For Further Information:
Simulations Plus, Inc.
42505 10th Street West
Lancaster, CA 93534-7059
CONTACT:
| Simulations Plus Investor Relations | Hayden IR |
| Ms. Renee Bouche | Mr. Cameron Donahue |
| 661-723-7723 | 651-653-1854 |
| renee@simulations-plus.com | cameron@haydenir.com |
For Immediate Release:
November 18, 2015
Simulations Plus Reports FY2015 and Fourth Quarter FY2015 Financial Results
Full Fiscal Year Pharmaceutical Software and Services Up 59.8%;
Earnings per share $0.23 cents up $0.05 cents (22.4%) over prior year
LANCASTER, CA, November 18, 2015 – Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, today reported its financial results for its 2015 fiscal year (FY15) and fourth quarter (4Q15) ended August 31, 2015.
Results for the 2015 fiscal year (FY15):
| · | Revenues were $18.31 million, representing an increase of 59.8% over $11.46 million in FY14 |
| · | Gross profit was up 42.4% to $14.0 million, an increase of $4.17 million from $9.83 million in FY14 |
| · | SG&A expense increased 53.5% to $6.81 million from $4.44 million in FY14 |
| o | As a percent of sales, SG&A decreased to 37.2% from 38.7% in FY14 |
| · | R&D expenditures were $2.50 million in FY15, an increase of 7.5% or $180,000, over $2.32 million in FY14 |
| o | For FY15, $1.17 million was capitalized and $1.33 million was expensed |
| o | For FY14, $1.37 million was capitalized and $953,000 was expensed |
| · | Net income was $3.84 million, representing an increase of 27.0% from $3.03 million in FY14 |
| · | Net income from operations increased 31.9% |
| · | Net income per fully diluted share was $0.226, representing an increase of 22.4% from $0.184 for FY14 |
| · | Cash decreased slightly to $8.55 million, a decrease of $60,000 or 0.01%, from $8.6 million at the end of FY14 after distributing approximately $3.4 million in dividends to shareholders, and using $2.1 million for the Cognigen acquisition |
Results for the fourth quarter FY15 (4Q15):
| · | Revenues were $3.71 million, representing an increase of 85.8% over $2.0 million in 4Q14 | |
| · | Gross profit was up 71.4% to $2.64 million, an increase of $1.1 million from $1.54 million | |
| · | SG&A increased 42.3% to $1.51 million from $1.06 million in 4Q14 | |
| · | R&D expenditures were $539,000, an increase of 3.9% from $519,000 in 4Q14 |
| o | For 4Q15, $193,000 was capitalized and $346,000 was expensed | |
| o | For 4Q14, $317,000 was capitalized and $202,000 was expensed |
| · | Net income was $491,000, representing an increase of 120.2% over $223,000 in 4Q14 | |
| · | Earnings per fully diluted share were $0.029, representing an increase of 114.2% over $0.013 in 4Q14 |
John Kneisel, chief financial officer for Simulations Plus, said: “Fiscal year 2015 was a banner year for Simulations Plus. The successful acquisition of Cognigen brought an additional $5.2 million of consulting revenues. Coupled with another strong year of organic growth of our flagship software products, we have completed another record financial year. 2015 diluted earnings per share were $0.23, a record year for the company. Cash balances of $8.55 million are substantially the same as the prior year, even after distributing $3.4 million in dividends, and using $2.1 million for the Cognigen acquisition.”
Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “Our continued growth is a tribute to our marketing and sales staff and our expanded scientific team, whose ongoing efforts to keep us out in front of the technologies in which we specialize have enabled us to hold onto our leadership position in a competitive market. New developments now underway are expected to continue this trend, and we believe our aggressive marketing and sales program and training workshops will continue to bolster our pipeline for continued growth.”
| 1 |
Mr. Woltosz continued, “With the strategic acquisition of our Buffalo division (Cognigen), we believe we are leading the way to the integration of mechanistic physiologically based pharmacokinetics (PBPK) modeling as a critical support tool for clinical pharmacology. This has been an exciting step forward for the combined companies, more than doubling the Simulations Plus workforce and adding synergistic capabilities to our traditional offerings.”
Dr. Ted Grasela, president of Simulations Plus and Cognigen, added, “The creative applications of our software to address challenges in pharmaceutical research and development are especially evident within the discipline of clinical pharmacology. Simulations Plus now has combined strengths in PBPK and in clinical pharmacology, which is a combination that is being encouraged by regulatory agencies worldwide.”
John DiBella, vice president for marketing and sales for Simulations Plus, said: “4Q15 was strong for both software sales and consulting services. Revenue from new licenses comprised 13% of total revenue, renewal rates exceeded 90%, and consulting service revenue comprised 42% of the total revenue. For FY15, 86 new organizations, or new departments at existing organizations, are now utilizing our technology, growing our installed base. Included among these new licenses were orders from major regulatory agencies in the US and Asia, along with companies outside our core pharmaceutical market. We also experienced a robust 91% account, and 95% revenue, renewal rate for the year. The consulting services division, which continues to maintain a robust project pipeline heading into 2016, had revenue that comprised 32% of total revenue in FY15. With our continued focus on education and training, increased marketing efforts, and the upcoming release of the standalone PKPlus™ application along with upgrades to several existing products, we believe we’re in an excellent position to address the needs set forth by regulatory agencies and capitalize on the increased adoption of modeling & simulation technology across industries.”
Investor Conference Call November 18, 2015, 4:15 p.m. EST/1:15 p.m. PST
The Company will hold an investor conference call on Wednesday November 18, 2015, at 1:15 p.m. PST/4:15 p.m. EST. The conference call will be webcast live and may be joined by registering at https://attendee.gotowebinar.com/register/8292239990300836609. Upon registering, you will receive a confirmation e-mail with instructions for joining the call. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial (646) 307-1720, and enter access code 235-661-318.
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of drug discovery and development software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. For more information, visit our website at www.simulations-plus.com.
Follow Us on Twitter
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of our new software products as well as improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.
| 2 |
SIMULATIONS PLUS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
As of August 31, 2015 and 2014
| ASSETS | |||||||
| 2015 | 2014 | ||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 8,551,275 | $ | 8,614,929 | |||
| Accounts receivable, net of allowance for doubtful accounts of $0 | 1,593,707 | 1,708,158 | |||||
| Revenues in excess of billings | 795,125 | 158,914 | |||||
| Prepaid income taxes | – | 748,359 | |||||
| Prepaid expenses and other current assets | 381,718 | 188,160 | |||||
| Deferred income taxes | 210,972 | 114,846 | |||||
| Total current assets | 11,532,797 | 11,533,366 | |||||
| Long-term assets | |||||||
| Capitalized computer software development costs, | |||||||
| net of accumulated amortization of $7,632,421 and $6,609,283 | 3,798,339 | 3,452,541 | |||||
| Property and equipment, net | 413,510 | 95,242 | |||||
| Intellectual property, net of accumulated amortization of $801,250 and $193,750 | 5,273,750 | 5,881,250 | |||||
| Other intangible assets net of accumulated amortization of $147,500 | 1,502,500 | – | |||||
| Goodwill | 4,789,248 | – | |||||
| Other assets | 34,082 | 18,445 | |||||
| Total assets | $ | 27,344,226 | $ | 20,980,844 | |||
| LIABILITIES AND SHAREHOLDERS' EQUITY | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 209,407 | $ | 130,547 | |||
| Accrued payroll and other expenses | 429,580 | 340,709 | |||||
| Accrued bonuses to officer | 121,000 | 120,000 | |||||
| Income taxes payable | 43,602 | – | |||||
| Other current liabilities | 19,859 | 19,859 | |||||
| Current portion - Contracts payable | 2,604,404 | 750,000 | |||||
| Billings in excess of revenues | 106,534 | – | |||||
| Deferred revenue | 78,945 | 30,370 | |||||
| Total current liabilities | 3,613,331 | 1,391,485 | |||||
| Long-term liabilities | |||||||
| Deferred income taxes | 3,190,419 | 2,375,874 | |||||
| Payments due under Contracts payable | 1,000,000 | 1,750,000 | |||||
| Other long-term liabilities | 8,274 | 28,134 | |||||
| Total liabilities | $ | 7,812,024 | $ | 5,545,493 | |||
| Commitments and contingencies | |||||||
| Shareholders' equity | |||||||
| Preferred stock, $0.001 par value | |||||||
| 10,000,000 shares authorized | |||||||
| no shares issued and outstanding | $ | – | $ | – | |||
| Common stock, $0.001 par value | |||||||
| 50,000,000 shares authorized | |||||||
| 16,943,001 and 16,349,955 shares issued and outstanding | 5,414 | 4,821 | |||||
| Additional paid-in capital | 9,714,290 | 6,085,427 | |||||
| Retained earnings | 9,812,498 | 9,345,103 | |||||
| Total shareholders' equity | $ | 19,532,202 | $ | 15,435,351 | |||
| Total liabilities and shareholders' equity | $ | 27,344,226 | $ | 20,980,844 | |||
| 3 |
SIMULATIONS PLUS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the year ended August 31,
| 2015 | 2014 | |||||||
| Net Revenues | $ | 18,314,248 | $ | 11,460,880 | ||||
| Cost of revenues | 4,315,870 | 1,629,069 | ||||||
| Gross margin | 13,998,378 | 9,831,811 | ||||||
| Operating expenses | ||||||||
| Selling, general, and administrative | 6,813,374 | 4,439,665 | ||||||
| Research and development | 1,328,476 | 952,774 | ||||||
| Total operating expenses | 8,141,850 | 5,392,439 | ||||||
| Income from operations | 5,856,528 | 4,439,372 | ||||||
| Other income (expense) | ||||||||
| Interest income | 17,935 | 31,437 | ||||||
| Gain(loss) on currency exchange | (181,534 | ) | 42,488 | |||||
| Total other income (expense) | (163,599 | ) | 73,925 | |||||
| Income from operations before provision for income taxes | 5,692,929 | 4,513,297 | ||||||
| Provision for income taxes | (1,849,968 | ) | (1,487,806 | ) | ||||
| Net Income | $ | 3,842,961 | $ | 3,025,491 | ||||
| Earnings per share | ||||||||
| Basic | $ | 0.23 | $ | 0.19 | ||||
| Diluted | $ | 0.23 | $ | 0.18 | ||||
| Weighted-average common shares outstanding | ||||||||
| Basic | 16,864,670 | 16,173,674 | ||||||
| Diluted | 17,032,158 | 16,407,751 |
The accompanying notes are an integral part of these financial statements.
| 4 |